The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer

BACKGROUND: Pancreatic cancer is a lethal malignancy that frequently acquires resistance to conventional chemotherapies often associated with overexpression of inhibitors of apoptosis proteins (IAPs). We have recently described a novel means to deliver second mitochondria-derived activator of caspas...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashim, Yassar M., Vangveravong, Suwanna, Sankpal, Narendra V., Binder, Pratibha S., Liu, Jingxia, Goedegebuure, S. Peter, Mach, Robert H., Spitzer, Dirk, Hawkins, William G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240213/
https://www.ncbi.nlm.nih.gov/pubmed/28095907
http://dx.doi.org/10.1186/s13046-016-0470-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240213/
https://www.ncbi.nlm.nih.gov/pubmed/28095907
http://dx.doi.org/10.1186/s13046-016-0470-4

Ejemplares similares